Drugs / resistant potato starch
resistant potato starch
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07443943 | Apr 2026 → Sep 2027 expected | breast carcinoma in situ, female breast carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05820893 | Feb 2025 → Jun 2027 expected | persian gulf syndrome | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT02763033 | Apr 2017 → Dec 2025 | disease related to hematopoietic stem cell transplant | University of Michigan Rogel Cancer Center | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | resistant potato starch | “This phase II trial tests the safety and effectiveness of a dietary supplement called resistant potato starch for reducing musculoskeletal symptoms in patients with stage 0-III...” NCT07443943 ↗2“Ten adults received resistant potato starch (RPS) daily from day -7 to day 100.” PMID 37857710 ↗ Oct 2023 |
| Known as | MSPrebiotic | “MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum).” NCT05820893 ↗ |
| Known as | RPS | “Ten adults received resistant potato starch (RPS) daily from day -7 to day 100.” PMID 37857710 ↗ Oct 2023 |
| Modality | Other / unclassified | “administering a commercially available dietary supplement containing potato-based resistant starch” NCT02763033 ↗ |
| Route | Oral | “Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.” NCT02763033 ↗ |